![A Phase 1, Open-label, Non-randomized, 2-period, Fixed Sequence Study To Investigate The Absorption, Metabolism And Excretion Of [14c-pf-04965842] And To Assess The Absolute Bioavailability And Fraction Absorbed Of Pf-04965842 In Healthy Male Subjects Using A 14c-microtracer Approach](https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/Adis_logo.png "A Phase 1, Open-label, Non-randomized, 2-period, Fixed Sequence Study To Investigate The Absorption, Metabolism And Excretion Of [14c-pf-04965842] And To Assess The Absolute Bioavailability And Fraction Absorbed Of Pf-04965842 In Healthy Male Subjects Using A 14c-microtracer Approach"){kind=logo}
Trial Profile
A Phase 1, Open-label, Non-randomized, 2-period, Fixed Sequence Study To Investigate The Absorption, Metabolism And Excretion Of [14c-pf-04965842] And To Assess The Absolute Bioavailability And Fraction Absorbed Of Pf-04965842 In Healthy Male Subjects Using A 14c-microtracer Approach
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Abrocitinib (Primary) ; Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Jun 2022 Results assessing the disposition of abrocitinib in male participants following oral and intravenous administration using accelerator mass spectroscopy methodology to estimate pharmacokinetic parameters and characterize metabolite profiles published in the Drug Metabolism and Disposition
- 06 Oct 2017 Status changed from recruiting to completed.
- 05 Sep 2017 Planned End Date changed from 15 Sep 2017 to 1 Sep 2017.